Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria Stephanie GreenGeoffrey R. Weiss OriginalPaper Pages: 239 - 253
Comparativein vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells Donna A. VolpeDe-Lin DuMartin J. Murphy OriginalPaper Pages: 255 - 261
Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique Saïk UrienGérard BastianJean-Paul Tillement OriginalPaper Pages: 263 - 268
Lack of effects of recombinant human interleukin-4 onin vitro colony formation of freshly explanted human tumor cells Axel -R. HanauskeDonna DegenDaniel D. Von Hoff OriginalPaper Pages: 269 - 273
Taxol administered as a 120 hour infusion David R. SpriggsCarlo Tondini OriginalPaper Pages: 275 - 278
Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days Howard BaileyPeter KohlerGeorge Wilding OriginalPaper Pages: 279 - 287
Clinical pharmacology studies of Oltipraz — A potential chemopreventive agent Nikolay V. DimitrovJames L. BennettWinfred Malone OriginalPaper Pages: 289 - 298
Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer Mark D. HaugeHarry J. LongJohn Su OriginalPaper Pages: 299 - 301
Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer L. KayitalireF. ThomasM. Spielmann OriginalPaper Pages: 303 - 307
A phase II trial of CI-921 in advanced malignancies Nancy T. SklarinPeter H. WiernikCharles D. Kowal OriginalPaper Pages: 309 - 312
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma Ephraim S. CasperGary K. SchwartzDavid P. Kelsen OriginalPaper Pages: 313 - 316
Phase II trial of pirarubicin in the treatment of advanced bladder cancer M. MahjoubiJ. KattanP. Herait OriginalPaper Pages: 317 - 321
Phase II study of gemcitabine in advanced colorectal adenocarcinoma Dennis F. Moore Jr.Richard PazdurJames L. Abbruzzese OriginalPaper Pages: 323 - 325
Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT Barbara A. MurphyRobert J. MotzerGeorge J. Bosl OriginalPaper Pages: 327 - 330
Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma Frank V. FossellaRodger J. WinnWaun Ki Hong OriginalPaper Pages: 331 - 335
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma G. FalksonM. HuntT. J. Smith OriginalPaper Pages: 337 - 343
A phase II investigation of pentostatin in metastatic malignant melanoma Michael GreverPaul BragerEarl Metz Brief Report Pages: 345 - 346
Phase II trial of merbarone in soft tissue sarcoma Eric H. KrautJackie BendettiJames H. Doroshow Brief Report Pages: 347 - 349
Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma Agustín AvilésJosé C. Díaz-MaqueoRenaldo Guzmán OriginalPaper Pages: 351 - 355